MDM2 and acute myeloid leukemia: Recently, Ho et al. investigated the role of MDM2 in AML after allo-HCT and reported that MDM2 inhibition was able to restore p53 activity, leading to increased MHC class II expression and higher frequencies of non-exhausted T-cells.